ATLANTA, GA – – (Businesswire – March 28, 2019) – – Holzer & Holzer, LLC is investigating whether certain statements made by Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”)(NASDAQ: OSMT) complied with federal securities laws. On March 27, 2019, after the markets closed, Osmotica announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo. The price of Osmotica stock declined following this news. If you purchased Osmotica shares and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.